Ziad Hijazi
Forskare vid Uppsala kliniska forskningscentrum (UCR)
- E-post:
- ziad.hijazi@ucr.uu.se
- Besöksadress:
- Dag Hammarskjölds väg 38
- Postadress:
- Uppsala Science Park
Dag Hammarskjölds väg 38
751 85 UPPSALA
Ladda ned kontaktuppgifter för Ziad Hijazi vid Uppsala kliniska forskningscentrum (UCR)
Docent vid Institutionen för medicinska vetenskaper; Kardiologi
- Besöksadress:
- Akademiska sjukhuset, Ingång 40, 5 tr
751 85 Uppsala - Postadress:
- Akademiska sjukhuset, Ingång 40, 5 tr
751 85 UPPSALA
Ladda ned kontaktuppgifter för Ziad Hijazi vid Institutionen för medicinska vetenskaper; Kardiologi
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Akademiska meriter:
Överläkare i kardiologi, Kardiologkliniken, Akademiska sjukhuset.
Docent i kardiologi, Institutionen för medicinska vetenskaper, Uppsala universitet.
Forskare vid Uppsala Clinical Research Center (UCR).
Publikationer
Urval av publikationer
- Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation (2017)
- Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor (2017)
- Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine (2016)
- Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation (2016)
- Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time (2016)
- The ABC (age, biomarkers, clinical history) stroke risk score (2016)
- Growth differentiation factor 15 is an independent marker of risk of major bleeding in atrial fibrillation (2016)
- External Validation Of The Biomarker-Based ABC-Bleeding Risk Score For Atrial Fibrillation (2016)
- The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation (2016)
- The ABC risk score for patients with atrial fibrillation Reply (2016)
- Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation (2016)
- Renal Function in Atrial Fibrillation A Multifaceted Dilemma (2016)
- External Validation Of The Biomarker-Based ABC-Stroke Risk Score For Atrial Fibrillation (2016)
- Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation (2016)
- The 'obesity paradox' in atrial fibrillation (2016)
- NT-proBNP is a powerful predictor for incident atrial fibrillation (2016)
- Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation (2015)
- Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation (2015)
- Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial (2015)
- Reply (2015)
- Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation (2015)
- External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation (2015)
- Stora studier av NOAK visar på gott och säkert strokeskydd (2015)
- Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation (2015)
- Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation (2014)
- Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation (2014)
- Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis (2014)
- A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score (2014)
- Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation (2014)
- High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial (2014)
- High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin (2014)
- Antikoagulation vid akut stroke med förmaksflimmer Fem frågor bör besvaras innan behandlingen kan anses vara evidensbaserad (2014)
- Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation (2014)
- Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation (2014)
- New Risk Markers in Atrial Fibrillation (2013)
- Reply (2013)
- Biomarkers in atrial fibrillation (2013)
- Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy" (2013)
- Combining High Sensitivity Troponin I and T Measurements Improves Prediction of Long-Term Clinical Outcomes in Patients With Atrial Fibrillation - An Aristotle Substudy (2013)
- N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation (2013)
- Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation (2012)
- Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation (2012)
Senaste publikationer
- Data standards for atrial fibrillation/flutter and catheter ablation (2023)
- Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation (2023)
- Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation (2023)
- Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function (2023)
- Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores (2023)
Alla publikationer
Artiklar
- Data standards for atrial fibrillation/flutter and catheter ablation (2023)
- Plasma angiopoietin-2 and its association with heart failure in patients with atrial fibrillation (2023)
- Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation (2023)
- Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function (2023)
- Individual net clinical outcome with oral anticoagulation in atrial fibrillation using the ABC-AF risk scores (2023)
- Heart rate and death and hospitalization for heart failure in patients with persistent or permanent atrial fibrillation (2023)
- ABC-AF-Stroke score predicts thromboembolism in non-anticoagulated patients following successful atrial fibrillation ablation (2023)
- Duration of Anticoagulation Interruption Before Invasive Procedures and Outcomes in Patients With Atrial Fibrillation (2022)
- Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model (2022)
- Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation (2022)
- Bone morphogenetic protein 10 (2022)
- The ABC-Stroke Score Refines Stroke Risk Stratification in Patients With Atrial Fibrillation at the Emergency Department (2022)
- Early Versus Delayed Non-Vitamin K Antagonist Oral Anticoagulant Therapy After Acute Ischemic Stroke in Atrial Fibrillation (TIMING) (2022)
- Association of GDF-15, hs-cTnT and NT-proBNP with coronary artery disease in patients undergoing elective angiography (2022)
- Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Left Ventricular Hypertrophy (2021)
- Biomarker-Based Risk Prediction With the ABC-AF Scores in Patients With Atrial Fibrillation Not Receiving Oral Anticoagulation (2021)
- Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients With Atrial Fibrillation After Acute Coronary Syndrome or Percutaneous Coronary Intervention (2021)
- Biomarker-based risk scores in atrial fibrillation (2021)
- Evaluation of the prognostic value of GDF-15, ABC-AF-bleeding score and ABC-AF-death score in patients with atrial fibrillation across different geographical areas (2021)
- Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. (2021)
- Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. (2021)
- Risk markers of incident atrial fibrillation in patients with coronary heart disease (2021)
- Natriuretic peptides and incident atrial fibrillation (2021)
- Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation (2020)
- Regional variation in clinical characteristics and outcomes in patients with atrial fibrillation (2020)
- Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin (2020)
- Stepwise mass screening for atrial fibrillation using N-terminal B-type natriuretic peptide (2020)
- Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial Fibrillation (2020)
- Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials (2020)
- Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation (2020)
- Cardiac troponin is associated with cardiac outcomes in men and women with atrial fibrillation, insights from the ARISTOTLE trial (2020)
- Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease (2020)
- Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. (2020)
- Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity (2019)
- International normalized ratio control and subsequent clinical outcomes in patients with atrial fibrillation using warfarin (2019)
- Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation (2019)
- Natriuretic peptide should be used as a routine tool for evaluation of patients with atrial fibrillation (2019)
- Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight (2019)
- Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation (2019)
- Risk of ischemic stroke and utility of CHA2DS2-VASc score in women and men with atrial fibrillation (2019)
- The Science of Prognosis in Psychiatry (2018)
- Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis (2018)
- A biomarker-based risk score to predict death in patients with atrial fibrillation (2018)
- Novel Prognostic Biomarkers For Ischemic Stroke In Patients With Atrial Fibrillation Using Multimarker Screening (2018)
- Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy (2018)
- New Biomarkers Associated With Cardiovascular Death In Patients With Atrial Fibrillation Using Multimarker Screening (2018)
- Comparison of bleeding risk scores in patients with atrial fibrillation (2018)
- Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers (2018)
- Use of Biomarkers to Predict Specific Causes of Death in Patients With Atrial Fibrillation (2018)
- Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time (2017)
- Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation (2017)
- Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation (2017)
- N-terminal pro B-type natriuretic peptide in systematic screening for atrial fibrillation (2017)
- Risk of stroke in women and men with atrial fibrillation and only one additional CHA2DS2-VASC risk factor (2017)
- Timing of oral anticoagulant therapy in acute ischemic stroke with atrial fibrillation (2017)
- Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine (2016)
- Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillation (2016)
- Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time (2016)
- The ABC (age, biomarkers, clinical history) stroke risk score (2016)
- External Validation Of The Biomarker-Based ABC-Bleeding Risk Score For Atrial Fibrillation (2016)
- The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation (2016)
- The ABC risk score for patients with atrial fibrillation Reply (2016)
- Cardiac biomarkers and left ventricular hypertrophy in relation to outcomes in patients with atrial fibrillation (2016)
- Renal Function in Atrial Fibrillation A Multifaceted Dilemma (2016)
- External Validation Of The Biomarker-Based ABC-Stroke Risk Score For Atrial Fibrillation (2016)
- Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation (2016)
- The 'obesity paradox' in atrial fibrillation (2016)
- NT-proBNP is a powerful predictor for incident atrial fibrillation (2016)
- Stroke and bleeding outcomes with apixaban versus warfarin in patients with high creatinine, low body weight or high age receiving standard dose apixaban for stroke prevention in atrial fibrillation (2015)
- Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillation (2015)
- Changes in Renal Function in Patients With Atrial Fibrillation An Analysis From the RE-LY Trial (2015)
- Reply (2015)
- Efficacy and safety of apixaban compared with warfarin in relation to renal function over time in patients with atrial fibrillation (2015)
- External validation of the biomarker-based ABC-stroke risk score for atrial fibrillation (2015)
- Stora studier av NOAK visar på gott och säkert strokeskydd (2015)
- Comparison of Cardiac Troponins I and T Measured with High-Sensitivity Methods for Evaluation of Prognosis in Atrial Fibrillation (2015)
- Interleukin-6 and C-reactive protein and risk for cardiovascular events and death in anticoagulated patients with atrial fibrillation (2014)
- Response to Letter Regarding Article, "Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation (2014)
- Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis (2014)
- A new biomarker based risk score for predicting major bleeding in atrial fibrillation - the ABC (age, biomarkers, current disease) risk score (2014)
- Importance of Persistent Elevation of Cardiac Biomarkers in Atrial Fibrillation (2014)
- High-Sensitivity Troponin I for Risk Assessment in Patients With Atrial Fibrillation Insights From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial (2014)
- High Sensitivity Troponin T and Risk Stratification in Patients with Atrial Fibrillation during Treatment with Apixaban or Warfarin (2014)
- Antikoagulation vid akut stroke med förmaksflimmer Fem frågor bör besvaras innan behandlingen kan anses vara evidensbaserad (2014)
- Growth Differentiation Factor 15, a Marker of Oxidative Stress and Inflammation, for Risk Assessment in Patients With Atrial Fibrillation (2014)
- Galectin-3 is associated with worse clinical outcome in patients with atrial fibrillation (2014)
- Reply (2013)
- Biomarkers in atrial fibrillation (2013)
- Response to Letter Regarding Article, "Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation: A Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Substudy" (2013)
- Combining High Sensitivity Troponin I and T Measurements Improves Prediction of Long-Term Clinical Outcomes in Patients With Atrial Fibrillation - An Aristotle Substudy (2013)
- N-Terminal Pro-B-Type Natriuretic Peptide for Risk Assessment in Patients With Atrial Fibrillation (2013)
- Cardiac Biomarkers Are Associated With an Increased Risk of Stroke and Death in Patients With Atrial Fibrillation (2012)
- Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation (2012)